A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer

Furukawa,Kinya; Ishida,Junzo; Inagaki,Masaharu; Takabe,Kazuhiko; Ishikawa,Shigemi; Sakai,Mitsuaki; Ichimura,Hideo; Kamiyama,Koichi; Kaburagi,Takayuki; Hayashihara,Kenji; Kishi,Koji; Saito,Makoto; Satoh,Hiroaki

doi:10.3892/etm.2011.360

January 2012 Volume 3 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January 2012 Volume 3 Issue 1

Full Size Image

Article

A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer

Authors:
- Kinya Furukawa
- Junzo Ishida
- Masaharu Inagaki
- Kazuhiko Takabe
- Shigemi Ishikawa
- Mitsuaki Sakai
- Hideo Ichimura
- Koichi Kamiyama
- Takayuki Kaburagi
- Kenji Hayashihara
- Koji Kishi
- Makoto Saito
- Hiroaki Satoh
View Affiliations / Copyright

Affiliations: Department of Chest Surgery, Tokyo Medical University, Ibaraki Medical Center, Ibaraki 300-0395, Japan, Tsuchiura Kyodo General Hospital, Ibaraki, Japan, University of Tsukuba Hospital, Ibaraki, Japan, Tsukuba Medical Center Hospital, Ibaraki, Japan, Tsukuba Kinen Hospital, Ibaraki, Japan, Ibaraki Prefectural Central Hospital, Ibaraki, Japan, Ibaraki Higashi Hospital, Ibaraki, Japan, Mito Kyodo General Hospital, Ibaraki, Japan
Pages: 53-59
|
Published online on: October 7, 2011

https://doi.org/10.3892/etm.2011.360
Expand metrics +

Abstract

There is no standard treatment and there are no clearly defined guidelines for the treatment of postoperative recurrent non-small-cell lung cancer (NSCLC). We performed a retrospective population-based study to assess the benefits of treatment with gefitinib in patients with a postoperative recurrence of NSCLC in general clinical practice. This retrospective population-based study was conducted on patients with postoperative recurrent NSCLC who had been treated with gefitinib at 14 institutions in Ibaraki Prefecture between July 2002 and September 2007. The objective response rate to gefitinib therapy was 37.6% for local and distant recurrence. The median survival time following the start of gefitinib therapy was 12 months, and the one-year and two-year survival rates were 48.9 and 28.9%, respectively. The median survival time of the females was 19 months, and the median survival time of the males was 9 months (p=0.002). Univariate analysis showed that female gender, adenocarcinoma, a performance status (PS) of 0-1 and absence of smoking history were favorable prognostic factors. Only female gender and a PS of 0-1 were independent statistically significant prognostic factors in the multivariate analysis. The rate of greater than grade 1 interstitial lung damage as an adverse event was 3.5%. Gefitinib is a feasible treatment for postoperative recurrent NSCLC in general clinical practice, and a good response and prolonged survival were obtained, similar to the findings reported in published clinical studies that were conducted on highly selected patients.

View Figures

View References

1.	M FukuokaS YanoG GiacconeMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)J Clin Oncol2122372246200310.1200/JCO.2003.10.03812748244
2.	MG KrisRB NataleRS HerbstEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA29021492158200310.1001/jama.290.16.214914570950
3.	SW HamTY KimKH LeeClinical predictors versus epidermal growth factor receptor mutation in gefitinib-treat non-small-cell lung cancer patientsLung Cancer54201207200610.1016/j.lungcan.2006.07.00716956694
4.	GC ChangCM TsaiKC ChenPredictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patientsJ Thorac Oncol1520525200610.1097/01243894-200607000-0000417409911
5.	T ItayaN YamaotoM AndoInfluence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancerCancer Sci98226230200710.1111/j.1349-7006.2006.00379.x17233840
6.	TJ LynchDW BellR SordellaActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Eng J Med35021292139200410.1056/NEJMoa04093815118073
7.	T MitsudomiT KosakaH EndohMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol23251320200510.1200/JCO.2005.00.992
8.	K HayashibaraH SatohY ShinoharaA population-based study of gefitinib in patients with non-small cell lung cancerMed Oncol26222227200910.1007/s12032-008-9110-y18975151
9.	I YoshinoT YohenaM KitajimaC UshijimaK NishiokaY IchinoseK SugimachiSurvival of non-small cell lung cancer patients with postoperative recurrence at distant organsAnn Thorac Cardiovasc Surg7204209200111578260
10.	S KudohH KatoY NishiwakiInterstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control studyAm J Respir Crit Care Med17713481357200810.1164/rccm.200710-1501OC18337594
11.	M NakagawaT NishimuraS TeramukaiInterstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02BMC Res Notes2157200910.1186/1756-0500-2-15719656374
12.	G GiacconeRS HerbstC ManegoldGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1J Clin Oncol22777784200410.1200/JCO.2004.08.00114990632
13.	RS HerbstG GiacconeJH SchillerGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2J Clin Oncol22785794200410.1200/JCO.2004.07.21514990633
14.	TS MokYL WuS ThongprasertGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med361947957200910.1056/NEJMoa081069919692680
15.	S MoritaI OkamotoK KobayashiCombined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutationsClin Cancer Res1544934498200910.1158/1078-0432.CCR-09-039119531624
16.	C GridelliA ArdizzoniJY DouillardRecent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic OncologyLung Cancer68319331201010.1016/j.lungcan.2009.11.01820036027
17.	F ShojiT YanoI YoshinoD MoriF YamasakiH KohnoY MaeharaThe characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adeno-carcinomaEur J Surg Oncol348993200810.1016/j.ejso.2007.03.00517449217
18.	J OkamiK TaniguchiM HigashiyamaPrognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancerOncology72234242200710.1159/00011294718176089
19.	M KondoT YokoyamaT FukuiMutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgeryLung Cancer50385391200510.1016/j.lungcan.2005.06.00816140420

Appendices

Appendix

The following principal investigators and institutions also belonged to the Ibaraki Advanced Lung Cancer Study Group and participated in this study: Saito T, Ibaraki Higashi Hospital; Kurishima K, Ohtsuka M, Hizawa N, Gotoh Y, Onizuka M, and Satoh Y, University of Tsukuba Hospital; Shinohara Y, Tsuchiura Kyodo General Hospital; Ishikawa H, Tsukuba Medical Center Hospital; Yamamoto Y, Hitachi General Hospital; Nawa T, Hitachi General Hospital; Funayama Y, Tsukuba Gakuen General Hospital; Matsumura T, Ibaraki Seinan General Hospital; Kagohashi K; Mito Kyodo General Hospital; Endo T, Mito Medical Center Hospital; Sumi M, Kensei General Hospital; Kashimoto T, Mito Saiseikai Hospital.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Appendices

Appendix

Related Articles